D. Pietronigro

发表

Stereotactic injection of DTI-015 into recurrent malignant gliomas: phase I/II trial.

S. Hassenbusch, N. Leeds, V. Levin, 2003, Neoplasia.

The possible role of free radical reactions in carcinogenesis.

E. Flamm, D. Pietronigro, H. Demopoulos, 1980, Journal of environmental pathology and toxicology.

Further studies on free-radical pathology in the major central nervous system disorders: effect of very high doses of methylprednisolone on the functional outcome, morphology, and chemistry of experimental spinal cord impact injury.

E. Flamm, D. Pietronigro, H. Demopoulos, 1982, Canadian journal of physiology and pharmacology.

Lenalidomide oral monotherapy in relapsed/refractory small lymphocytic non-Hodgkin's lymphoma

J. Vose, K. Takeshita, C. Reeder, 2008 .

The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non‐Hodgkin lymphoma of distinct histological origin

J. Vose, M. Czuczman, P. Zinzani, 2011, British journal of haematology.

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

I. Lossos, J. Vose, T. Habermann, 2009, British journal of haematology.

DTI-015 produces cures in T9 gliosarcoma.

H. Cravioto, J. Ransohoff, D. Pietronigro, 2003, Neoplasia.

Interaction of DNA and liposomes as a model for membrane-mediated DNA damage

D. Pietronigro, H. Demopoulos, W. Jones, 1977, Nature.

Ascorbic acid: a putative biochemical marker of irreversible neurologic functional loss following spinal cord injury.

E. Flamm, D. Pietronigro, H. Demopoulos, 1985, Central nervous system trauma : journal of the American Paralysis Association.

Implications of Free Radical Activation for Improved Anthracycline Therapy

D. Pietronigro, 1982 .

Reductive metabolism of ascorbic acid in the central nervous system

E. Flamm, D. Pietronigro, H. Demopoulos, 1985, Brain Research.

The free radical pathology and the microcirculation in the major central nervous system disorders.

E. Flamm, D. Pietronigro, H. Demopoulos, 1980, Acta physiologica Scandinavica. Supplementum.

Effect of difluoromethylornithine on the antiglioma therapeutic efficacy of intra-arterial BCNU.

H. Cravioto, E. Flamm, D. Pietronigro, 1986, Journal of neurosurgery.

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.

I. Lossos, J. Vose, T. Habermann, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma.

J. Vose, M. Czuczman, R. Bouabdallah, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Single‐agent lenalidomide is active in patients with relapsed or refractory aggressive non‐Hodgkin lymphoma who received prior stem cell transplantation

I. Lossos, J. Vose, M. Czuczman, 2013, British journal of haematology.

Lenalidomide oral monotherapy produces durable responses in relapsed or refractory indolent non-Hodgkin's Lymphoma.

J. Vose, K. Takeshita, C. Reeder, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Development of Secondary Pathology with free Radical Reactions as a Threshold Mechanism

D. Pietronigro, H. Demopoulos, M. Seligman, 1983 .

Retarding effects of DNA on the autoxidation of liposomal suspensions

D. Pietronigro, H. Demopoulos, M. Seligman, 1976, Lipids.

Preliminary results from a phase I/II study of the combination of lenalidomide and DTIC in patients with metastatic malignant melanoma previously untreated with systemic chemotherapy

P. Hwu, J. Zeldis, A. Bedikian, 2007 .

Durable Responses After Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory (R/R) Aggressive Non-Hodgkin's Lymphoma (a-NHL): Results From An International Phase 2 Study (CC-5013-NHL-003).

J. Vose, M. Czuczman, P. Zinzani, 2009 .

Intratumoral injection of BCNU in ethanol (DTI-015) results in enhanced delivery to tumor – a pharmacokinetic study

Daniel E. Hall, K. Frey, B. Ross, 2005, Journal of Neuro-Oncology.

Formation of DNA adducts and tumor growth delay following intratumoral administration of DTI-015

V. Levin, W. Bodell, D. Pietronigro, 2003, Journal of Neuro-Oncology.

Direct quenching of adriamycin radicals by coenzyme Q10 and tetrazolium salts.

D. Pietronigro, J. Mignano, H. Demopoulos, 1983, Biochemical pharmacology.

Preliminary Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Aggressive Non-Hodgkin’s Lymphoma.

I. Lossos, J. Vose, T. Habermann, 2006 .

Expanded safety experience with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma

P. Richardson, Shaji K. Kumar, D. Reece, 2009, British journal of haematology.

International study of lenalidomide in relapsed/refractory aggressive non-Hodgkin’s lymphoma

M. Czuczman, C. Reeder, T. Witzig, 2008 .

Therapeutic Efficacy of DTI-015 using Diffusion Magnetic Resonance Imaging as an Early Surrogate Marker

Bradford A Moffat, Timothy D Johnson, Alnawaz Rehemtulla, 2004, Clinical Cancer Research.

Confirmation of the Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Relapsed or Refractory Mantle-Cell Lymphoma: Results of An International Study (NHL-003)

J. Vose, M. Czuczman, R. Bouabdallah, 2008 .

Expanded Access Program (EAP) for Lenalidomide (Revlimid®) Plus Dexamethasone in over 1400 Subjects with Relapsed or Refractory Multiple Myeloma.

Shaji K. Kumar, D. Reece, J. Zeldis, 2006 .

Efficacy and safety of lenalidomide oral monotherapy in patients with relapsed or refractory mantle-cell lymphoma: Results from an international study (NHL-003).

J. Vose, M. Czuczman, R. Bouabdallah, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Efficacy and Safety of Lenalidomide Oral Monotherapy in Patients with Mantle Cell Lymphoma Previously Treated with Bortezomib: Pooled Data from Two Phase II Studies (NHL-002 and NHL-003).

J. Vose, M. Czuczman, R. Bouabdallah, 2008 .

Lenalidomide Oral Monotherapy Produces a 53% Response Rate in Patients with Relapsed/Refractory Mantle-Cell Non-Hodgkin’s Lymphoma.

I. Lossos, J. Vose, T. Habermann, 2007 .

Early Results from a Phase II Study of Lenalidomide Monotherapy in Relapsed/Refractory Indolent Non-Hodgkin’s Lymphoma.

J. Vose, K. Takeshita, T. Witzig, 2006 .

Spontaneous generation of adriamycin semiquinone radicals at physiologic pH.

D. Pietronigro, J. McGinness, R. Crippa, 1979, Physiological chemistry and physics.

Efficacy of lenalidomide oral monotherapy in relapsed or refractory indolent non-Hodgkin's lymphoma: Final results of NHL-001.

J. Vose, C. Reeder, T. Witzig, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.